Skip to main content

Table 4 Multivariate analysis of prognostic factors for progression-free survival and overall survival

From: Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

Variables

Hazard ratio

95% CI

P value

PFS

No. of involved extranodal organ

   

   OED

1

  

   MED

4.11

1.28-13.2

0.017

IPI

   

   Low to low-intermediate

1

  

   High-intermediate to high

3.35

1.05-10.72

0.042

Treatment strategy

   

   ≥4cycles ± any local modalities

1

  

   <4cycles ± any local modalities

3.90

1.30-11.70

0.015

OS

No. of involved extranodal organ

   

   OED

1

  

   MED

3.61

1.07-12.20

0.039

IPI

   

   Low to low-intermediate

1

  

   High-intermediate to high

3.58

0.99-12.98

0.052

Treatment strategy

   

   ≥4cycles ± any local modalities

1

  

   <4cycles ± any local modalities

4.47

1.54-12.96

0.006

  1. Abbreviation: PFS, progression-free survival; OS, overall survival; CI, confidence interval; OED, one extranodal disease in the breast; MED, multiple extranodal disease; IPI, international prognostic index.